Chromadex (NASDAQ:CDXC) and Cronos Group (NASDAQ:CRON) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, institutional ownership, valuation, earnings and analyst recommendations.
Institutional & Insider Ownership
16.2% of Chromadex shares are held by institutional investors. Comparatively, 9.8% of Cronos Group shares are held by institutional investors. 10.3% of Chromadex shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
This is a breakdown of current recommendations for Chromadex and Cronos Group, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Chromadex currently has a consensus target price of $8.00, indicating a potential upside of 120.39%. Cronos Group has a consensus target price of $4.50, indicating a potential downside of 47.37%. Given Chromadex’s stronger consensus rating and higher probable upside, analysts plainly believe Chromadex is more favorable than Cronos Group.
Earnings and Valuation
This table compares Chromadex and Cronos Group’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Chromadex||$21.20 million||9.43||-$11.37 million||($0.35)||-10.37|
|Cronos Group||$3.15 million||480.92||$1.92 million||$0.01||855.00|
Cronos Group has lower revenue, but higher earnings than Chromadex. Chromadex is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.
This table compares Chromadex and Cronos Group’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Cronos Group beats Chromadex on 8 of the 13 factors compared between the two stocks.
ChromaDex Corporation operates as a nutraceutical company. The company offers research and quality control products and services to dietary supplements, food, beverages, cosmetic, and pharmaceutical industries; Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide(NAD) level used for healthy aging; Pterostilbene (pTeroPure), a polyphenol and antioxidant used in health related fields; and Immulina, a spirulina extract and compound, which is used for improving human immune function, as well as developing Pterostilbene and caffeine co-crystal ingredients, and anthocyanins ingredients. It also provides reference standards, materials, and kits to conduct quality control of raw materials and consumer products; and fine chemicals and phytochemicals for research and new product development applications. In addition, the company offers a range of consulting services, including regulatory support, product development, risk management, and litigation support. Further, it assists customers in creating processes for manufacturing natural products using green chemistry, as well as developing phytochemical libraries. The company markets and sells its products directly in the United States and Canada; and through international distributors. ChromaDex Corporation is based in Irvine, California.
About Cronos Group
Cronos Group Inc., formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada's Marihuana for Medical Purposes Regulations MMPR. The firm typically invests in companies based in Canada. The firm is primarily an equity investor, may also advance debt as appropriate. It seeks to make minority investments with appropriate governance and shareholder rights. The firm seeks board representation consistent with the size of the investment, but does not need control. Cronos Group Inc. was incorporated in January, 2013 and is based in Toronto, Canada with an additional office in Toronto, Canada.
Receive News & Ratings for Chromadex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromadex and related companies with MarketBeat.com's FREE daily email newsletter.